期刊文献+

尿路上皮性肿瘤肿瘤标志物研究进展

下载PDF
导出
摘要 尿路上皮肿瘤作为泌尿系统最常见的恶性肿瘤,要求得到及早发现和诊断,方能提高治疗效果,降低死亡率。传统的膀胱镜诊断方法具有侵入性局限性,尿细胞学检查属无创并且特异度高,但敏感度低。对于上尿路上皮肿瘤肿瘤标志物的报道少见,因而寻找无创、敏感度及特异性高且简单可行的肿瘤标志物作为尿路上皮肿瘤诊断和随访的依据成为近年研究的热点。端粒酶、NMP22、膀胱肿瘤抗原等膀胱癌肿瘤标志物已经得到广泛研究,且日趋成熟。新的肿瘤标志物如纤维素和纤维蛋白降解产物(FB/FDP)、BLCA以及各种肿瘤标志物联合应用诊断尿路上皮肿瘤的研究也获得长足进展,显示出良好的应用价值。
作者 陈智 梁培育
出处 《贵阳中医学院学报》 2009年第3期70-73,共4页 Journal of Guiyang University of Chinese Medicine
  • 相关文献

参考文献21

  • 1Lokeshwar VB,Block NL.HA/HAase urine test.A sensitive and specific method for detecting bladder cancer and evaluating its grade.Urol Clin North Am,2000,27:53.
  • 2Erdem E,DikmenG,AtsuN,eta.1 Telomerase activity in diagnosis of bladder cancer.Scand JUrolNephrol2003,37:205-209.
  • 3Ponsky LE,Sharma S,Pandrangi L,et al.Screening and monitoring for bladder cancer:refining the use of NMP22.J Urol,2001,166(1):75-78.
  • 4Koncty BR,Nguyen TST.Brenes G,et al.Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer.JUrol,2000,164:634-639.
  • 5Takashi M,Schenck U,Kissel K,et al.Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.Int Urol Nephrol,1999,31:189.
  • 6Glas AS,Roos D,Deutekom,et al.Tumor markers in the diagnosis of primary bladder cancer.A systematic review.J Urol,2003,169(6):1975-1982.
  • 7Mahnert B,Tauber S,Kriegmair M,et al.Measurements of complement factor H-related protein(BTA-TRAK assay)and nuclear matrix protein(NMP-22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer?Clin Chem Lab Med,2003,41(1):104-110.
  • 8Nisman B,Barak V,Shapiro A,et al.Evaluation of urine CYFRA21-1 for the detection of primary and recurrent bladder carcinoma.Cancer,2002,9:2914-2922.
  • 9Shariat SF,Casella R,Khoddami SM,et al.Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.J Urol,2004,171:626.
  • 10Swana HS.Grossman D,Anthony JN,et al.Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.NEngl J Med,1999,341:452-453.

二级参考文献29

  • 1张爱民,李慎勤,杨德安,李香铁,王洪伟,韩玮,刘仰东.BTA试验、尿β-HCG测定及尿液细胞学检查联合诊断膀胱肿瘤[J].中华泌尿外科杂志,1996,17(12):761-761. 被引量:1
  • 2Pariente J L, Bordenave L, Michel P, et al. Initial evaluation of CYFRA21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma [J]. J Urol, 1997,158 ( 1 ): 338-342.
  • 3Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer[J].Science, 1994,266(23) :2011-2015.
  • 4Jones A, Fujiyama C. Angiogenesis in urological malignancy:Prognostic indicator and therapeutic target[J]. Br J Urol, 1999,83(5) :535-556.
  • 5Sanchez-Carbayo M, Herrero E, Meglas J, et al. Comparative sensitivity of urinary CYFRA21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer[J]. J Urol, 1999,162(6): 1951-1956.
  • 6Giannopoulos A, Manousakas T, Gounari A, et al. Comparative evaluation of the diagnostic performance of the BTA stat test,NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors[J]. J Urol, 2001, 166(2):470-475.
  • 7Landman J, Chang Y, Kavaler E, et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer [J]. Urology, 1998,52 (3): 398-404.
  • 8Crew JP, O'Brien T, Bradburm M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer [ J ]. Cancer Res, 1997, 57 ( 23 ): 5281-5285.
  • 9Sozen S,Eskicorabci E,Ozen H.Urinary makers for urothelial cancer.BJU Int,2003,92:531-533.
  • 10Mian C,Lodde M,Haitel A,et al.Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.Urology,2000,55:223-226.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部